Global Orphan Diseases Market

Orphan Diseases Comprehensive Study by Disease Type (Oncology, Allergic and Immunologic Disorders, Cardiac and Vascular Conditions, Infectious Diseases, Neurologic Conditions, Skin and Soft Tissue Conditions, Benign Neoplasms, Hematologic Disorders, Musculoskeletal Conditions, Others), Age Group (Children, Adults), Treatment Type (Medication (Powder, Tablets/Capsules, Injectable), Cell & Gene Therapy, Antibody Therapy, Enzyme Replacement) Players and Region - Global Market Outlook to 2030

Orphan Diseases Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Orphan Diseases Market Overview:
Rare diseases are a group of diseases that affect a small number of people. In general, disease affects less than 1-5 people per 10,000 general population is considered as rare disease. The increased focus of researchers and the FDA on therapies for rare diseases has led to a dramatic increase in the number of new therapeutic options for rare disease patients. Main driving factor for the rare disease market is rising rare diseases and its incidence cases and thereby the demand for orphan drugs are continue to rise. Growing occurrence of several types of rare cancers, blood related disorders, rare diseases related to central nervous systems are considered as prominent carter of the demand surge. Therefore, rare disease drugs are anticipated to receive huge demand and growth during the forecasted years.

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Advances in Genomics As Well As the More Mainstream Use of Gene Sequencing

Market Growth Drivers:
Rising Prevalence of Rare Diseases Across the Globe and Increased Spending on Research and Development Activities by Major Players

Challenges:
Limited Healthcare Infrastructure and Resources Can Impact the Delivery and Management of Orphan Disease Treatments

Restraints:
Premium Pricing for Orphan Drugs is Likely to Hamper the Growth

Opportunities:
Adoption of New Life-Changing Therapies for Rare Disease Treatment and Regulatory Grants & Initiatives Concentrating on Unmet Needs

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Bristo Myers Squibb (United States), Amgen Inc. (United States), AstraZeneca (United Kingdom), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (United States), Sanofi (France), Merck KGaA (Germany), Eli Lilly and Company (United States), Johnson & Johnson (United States), AbbVie Inc. (United States) and Gilead Sciences, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Orphan Diseases market by 2030. Considering Market by Disease Type, the sub-segment i.e. Oncology will boost the Orphan Diseases market. Considering Market by Age Group, the sub-segment i.e. Children will boost the Orphan Diseases market. Considering Market by Treatment Type, the sub-segment i.e. Medication (Powder, Tablets/Capsules, Injectable) will boost the Orphan Diseases market.

Latest Market Insights:
In July 2021, AstraZeneca acquired Alexion Pharmaceuticals, Inc. (Alexion). The closing of the acquisition marks the Company’s entry into medicines for rare diseases and the beginning of a new chapter for AstraZeneca. AstraZeneca now has an enhanced scientific presence in immunology and, through Alexion’s innovative complement-biology platform and robust pipeline, will continue to pioneer the discovery and development of medicines for patients with rare diseases.



What Can be Explored with the Orphan Diseases Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Orphan Diseases Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Orphan Diseases
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Orphan Diseases market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Orphan Diseases market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Drug Manufacturers, Biotech Companies, Government Regulatory Bodies, Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Disease Type
  • Oncology
  • Allergic and Immunologic Disorders
  • Cardiac and Vascular Conditions
  • Infectious Diseases
  • Neurologic Conditions
  • Skin and Soft Tissue Conditions
  • Benign Neoplasms
  • Hematologic Disorders
  • Musculoskeletal Conditions
  • Others

By Age Group
  • Children
  • Adults

By Treatment Type
  • Medication (Powder, Tablets/Capsules, Injectable)
  • Cell & Gene Therapy
  • Antibody Therapy
  • Enzyme Replacement

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Rare Diseases Across the Globe
      • 3.2.2. Increased Spending on Research and Development Activities by Major Players
    • 3.3. Market Challenges
      • 3.3.1. Limited Healthcare Infrastructure and Resources Can Impact the Delivery and Management of Orphan Disease Treatments
    • 3.4. Market Trends
      • 3.4.1. Advances in Genomics As Well As the More Mainstream Use of Gene Sequencing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Orphan Diseases, by Disease Type, Age Group, Treatment Type and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Orphan Diseases (Value)
      • 5.2.1. Global Orphan Diseases by: Disease Type (Value)
        • 5.2.1.1. Oncology
        • 5.2.1.2. Allergic and Immunologic Disorders
        • 5.2.1.3. Cardiac and Vascular Conditions
        • 5.2.1.4. Infectious Diseases
        • 5.2.1.5. Neurologic Conditions
        • 5.2.1.6. Skin and Soft Tissue Conditions
        • 5.2.1.7. Benign Neoplasms
        • 5.2.1.8. Hematologic Disorders
        • 5.2.1.9. Musculoskeletal Conditions
        • 5.2.1.10. Others
      • 5.2.2. Global Orphan Diseases by: Age Group (Value)
        • 5.2.2.1. Children
        • 5.2.2.2. Adults
      • 5.2.3. Global Orphan Diseases by: Treatment Type (Value)
        • 5.2.3.1. Medication (Powder, Tablets/Capsules, Injectable)
        • 5.2.3.2. Cell & Gene Therapy
        • 5.2.3.3. Antibody Therapy
        • 5.2.3.4. Enzyme Replacement
      • 5.2.4. Global Orphan Diseases Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Orphan Diseases: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristo Myers Squibb (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amgen Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AstraZeneca (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck KGaA (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. AbbVie Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Gilead Sciences, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Orphan Diseases Sale, by Disease Type, Age Group, Treatment Type and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Orphan Diseases (Value)
      • 7.2.1. Global Orphan Diseases by: Disease Type (Value)
        • 7.2.1.1. Oncology
        • 7.2.1.2. Allergic and Immunologic Disorders
        • 7.2.1.3. Cardiac and Vascular Conditions
        • 7.2.1.4. Infectious Diseases
        • 7.2.1.5. Neurologic Conditions
        • 7.2.1.6. Skin and Soft Tissue Conditions
        • 7.2.1.7. Benign Neoplasms
        • 7.2.1.8. Hematologic Disorders
        • 7.2.1.9. Musculoskeletal Conditions
        • 7.2.1.10. Others
      • 7.2.2. Global Orphan Diseases by: Age Group (Value)
        • 7.2.2.1. Children
        • 7.2.2.2. Adults
      • 7.2.3. Global Orphan Diseases by: Treatment Type (Value)
        • 7.2.3.1. Medication (Powder, Tablets/Capsules, Injectable)
        • 7.2.3.2. Cell & Gene Therapy
        • 7.2.3.3. Antibody Therapy
        • 7.2.3.4. Enzyme Replacement
      • 7.2.4. Global Orphan Diseases Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Orphan Diseases: by Disease Type(USD Million)
  • Table 2. Orphan Diseases Oncology , by Region USD Million (2018-2023)
  • Table 3. Orphan Diseases Allergic and Immunologic Disorders , by Region USD Million (2018-2023)
  • Table 4. Orphan Diseases Cardiac and Vascular Conditions , by Region USD Million (2018-2023)
  • Table 5. Orphan Diseases Infectious Diseases , by Region USD Million (2018-2023)
  • Table 6. Orphan Diseases Neurologic Conditions , by Region USD Million (2018-2023)
  • Table 7. Orphan Diseases Skin and Soft Tissue Conditions , by Region USD Million (2018-2023)
  • Table 8. Orphan Diseases Benign Neoplasms , by Region USD Million (2018-2023)
  • Table 9. Orphan Diseases Hematologic Disorders , by Region USD Million (2018-2023)
  • Table 10. Orphan Diseases Musculoskeletal Conditions , by Region USD Million (2018-2023)
  • Table 11. Orphan Diseases Others , by Region USD Million (2018-2023)
  • Table 12. Orphan Diseases: by Age Group(USD Million)
  • Table 13. Orphan Diseases Children , by Region USD Million (2018-2023)
  • Table 14. Orphan Diseases Adults , by Region USD Million (2018-2023)
  • Table 15. Orphan Diseases: by Treatment Type(USD Million)
  • Table 16. Orphan Diseases Medication (Powder, Tablets/Capsules, Injectable) , by Region USD Million (2018-2023)
  • Table 17. Orphan Diseases Cell & Gene Therapy , by Region USD Million (2018-2023)
  • Table 18. Orphan Diseases Antibody Therapy , by Region USD Million (2018-2023)
  • Table 19. Orphan Diseases Enzyme Replacement , by Region USD Million (2018-2023)
  • Table 20. South America Orphan Diseases, by Country USD Million (2018-2023)
  • Table 21. South America Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 22. South America Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 23. South America Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 24. Brazil Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 25. Brazil Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 26. Brazil Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 27. Argentina Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 28. Argentina Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 29. Argentina Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 30. Rest of South America Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 31. Rest of South America Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 32. Rest of South America Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 33. Asia Pacific Orphan Diseases, by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 35. Asia Pacific Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 36. Asia Pacific Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 37. China Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 38. China Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 39. China Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 40. Japan Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 41. Japan Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 42. Japan Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 43. India Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 44. India Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 45. India Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 46. South Korea Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 47. South Korea Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 48. South Korea Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 49. Taiwan Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 50. Taiwan Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 51. Taiwan Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 52. Australia Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 53. Australia Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 54. Australia Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 55. Rest of Asia-Pacific Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 56. Rest of Asia-Pacific Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 57. Rest of Asia-Pacific Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 58. Europe Orphan Diseases, by Country USD Million (2018-2023)
  • Table 59. Europe Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 60. Europe Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 61. Europe Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 62. Germany Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 63. Germany Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 64. Germany Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 65. France Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 66. France Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 67. France Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 68. Italy Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 69. Italy Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 70. Italy Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 71. United Kingdom Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 72. United Kingdom Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 73. United Kingdom Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 74. Netherlands Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 75. Netherlands Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 76. Netherlands Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 77. Rest of Europe Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 78. Rest of Europe Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 79. Rest of Europe Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 80. MEA Orphan Diseases, by Country USD Million (2018-2023)
  • Table 81. MEA Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 82. MEA Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 83. MEA Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 84. Middle East Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 85. Middle East Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 86. Middle East Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 87. Africa Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 88. Africa Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 89. Africa Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 90. North America Orphan Diseases, by Country USD Million (2018-2023)
  • Table 91. North America Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 92. North America Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 93. North America Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 94. United States Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 95. United States Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 96. United States Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 97. Canada Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 98. Canada Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 99. Canada Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 100. Mexico Orphan Diseases, by Disease Type USD Million (2018-2023)
  • Table 101. Mexico Orphan Diseases, by Age Group USD Million (2018-2023)
  • Table 102. Mexico Orphan Diseases, by Treatment Type USD Million (2018-2023)
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Orphan Diseases: by Disease Type(USD Million)
  • Table 116. Orphan Diseases Oncology , by Region USD Million (2025-2030)
  • Table 117. Orphan Diseases Allergic and Immunologic Disorders , by Region USD Million (2025-2030)
  • Table 118. Orphan Diseases Cardiac and Vascular Conditions , by Region USD Million (2025-2030)
  • Table 119. Orphan Diseases Infectious Diseases , by Region USD Million (2025-2030)
  • Table 120. Orphan Diseases Neurologic Conditions , by Region USD Million (2025-2030)
  • Table 121. Orphan Diseases Skin and Soft Tissue Conditions , by Region USD Million (2025-2030)
  • Table 122. Orphan Diseases Benign Neoplasms , by Region USD Million (2025-2030)
  • Table 123. Orphan Diseases Hematologic Disorders , by Region USD Million (2025-2030)
  • Table 124. Orphan Diseases Musculoskeletal Conditions , by Region USD Million (2025-2030)
  • Table 125. Orphan Diseases Others , by Region USD Million (2025-2030)
  • Table 126. Orphan Diseases: by Age Group(USD Million)
  • Table 127. Orphan Diseases Children , by Region USD Million (2025-2030)
  • Table 128. Orphan Diseases Adults , by Region USD Million (2025-2030)
  • Table 129. Orphan Diseases: by Treatment Type(USD Million)
  • Table 130. Orphan Diseases Medication (Powder, Tablets/Capsules, Injectable) , by Region USD Million (2025-2030)
  • Table 131. Orphan Diseases Cell & Gene Therapy , by Region USD Million (2025-2030)
  • Table 132. Orphan Diseases Antibody Therapy , by Region USD Million (2025-2030)
  • Table 133. Orphan Diseases Enzyme Replacement , by Region USD Million (2025-2030)
  • Table 134. South America Orphan Diseases, by Country USD Million (2025-2030)
  • Table 135. South America Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 136. South America Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 137. South America Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 138. Brazil Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 139. Brazil Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 140. Brazil Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 141. Argentina Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 142. Argentina Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 143. Argentina Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 144. Rest of South America Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 145. Rest of South America Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 146. Rest of South America Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 147. Asia Pacific Orphan Diseases, by Country USD Million (2025-2030)
  • Table 148. Asia Pacific Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 149. Asia Pacific Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 150. Asia Pacific Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 151. China Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 152. China Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 153. China Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 154. Japan Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 155. Japan Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 156. Japan Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 157. India Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 158. India Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 159. India Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 160. South Korea Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 161. South Korea Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 162. South Korea Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 163. Taiwan Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 164. Taiwan Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 165. Taiwan Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 166. Australia Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 167. Australia Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 168. Australia Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 169. Rest of Asia-Pacific Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 170. Rest of Asia-Pacific Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 171. Rest of Asia-Pacific Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 172. Europe Orphan Diseases, by Country USD Million (2025-2030)
  • Table 173. Europe Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 174. Europe Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 175. Europe Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 176. Germany Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 177. Germany Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 178. Germany Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 179. France Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 180. France Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 181. France Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 182. Italy Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 183. Italy Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 184. Italy Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 185. United Kingdom Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 186. United Kingdom Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 187. United Kingdom Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 188. Netherlands Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 189. Netherlands Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 190. Netherlands Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 191. Rest of Europe Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 192. Rest of Europe Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 193. Rest of Europe Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 194. MEA Orphan Diseases, by Country USD Million (2025-2030)
  • Table 195. MEA Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 196. MEA Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 197. MEA Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 198. Middle East Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 199. Middle East Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 200. Middle East Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 201. Africa Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 202. Africa Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 203. Africa Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 204. North America Orphan Diseases, by Country USD Million (2025-2030)
  • Table 205. North America Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 206. North America Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 207. North America Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 208. United States Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 209. United States Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 210. United States Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 211. Canada Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 212. Canada Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 213. Canada Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 214. Mexico Orphan Diseases, by Disease Type USD Million (2025-2030)
  • Table 215. Mexico Orphan Diseases, by Age Group USD Million (2025-2030)
  • Table 216. Mexico Orphan Diseases, by Treatment Type USD Million (2025-2030)
  • Table 217. Research Programs/Design for This Report
  • Table 218. Key Data Information from Secondary Sources
  • Table 219. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Orphan Diseases: by Disease Type USD Million (2018-2023)
  • Figure 5. Global Orphan Diseases: by Age Group USD Million (2018-2023)
  • Figure 6. Global Orphan Diseases: by Treatment Type USD Million (2018-2023)
  • Figure 7. South America Orphan Diseases Share (%), by Country
  • Figure 8. Asia Pacific Orphan Diseases Share (%), by Country
  • Figure 9. Europe Orphan Diseases Share (%), by Country
  • Figure 10. MEA Orphan Diseases Share (%), by Country
  • Figure 11. North America Orphan Diseases Share (%), by Country
  • Figure 12. Global Orphan Diseases share by Players 2023 (%)
  • Figure 13. Global Orphan Diseases share by Players (Top 3) 2023(%)
  • Figure 14. Global Orphan Diseases share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Bristo Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 17. Bristo Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 18. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 20. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 22. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 24. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 26. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 29. Sanofi (France) Revenue: by Geography 2023
  • Figure 30. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 32. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 33. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 34. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 35. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 36. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 38. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Gilead Sciences, Inc. (United States) Revenue: by Geography 2023
  • Figure 40. Global Orphan Diseases: by Disease Type USD Million (2025-2030)
  • Figure 41. Global Orphan Diseases: by Age Group USD Million (2025-2030)
  • Figure 42. Global Orphan Diseases: by Treatment Type USD Million (2025-2030)
  • Figure 43. South America Orphan Diseases Share (%), by Country
  • Figure 44. Asia Pacific Orphan Diseases Share (%), by Country
  • Figure 45. Europe Orphan Diseases Share (%), by Country
  • Figure 46. MEA Orphan Diseases Share (%), by Country
  • Figure 47. North America Orphan Diseases Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bristo Myers Squibb (United States)
  • Amgen Inc. (United States)
  • AstraZeneca (United Kingdom)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Sanofi (France)
  • Merck KGaA (Germany)
  • Eli Lilly and Company (United States)
  • Johnson & Johnson (United States)
  • AbbVie Inc. (United States)
  • Gilead Sciences, Inc. (United States)
Select User Access Type

Key Highlights of Report


Sep 2024 221 Pages 83 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Orphan Diseases Market Quantitative research analysis
Global Orphan Diseases Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Orphan Diseases market are Bristo Myers Squibb (United States), Amgen Inc. (United States), AstraZeneca (United Kingdom), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (United States), Sanofi (France), Merck KGaA (Germany), Eli Lilly and Company (United States), Johnson & Johnson (United States), AbbVie Inc. (United States) and Gilead Sciences, Inc. (United States), to name a few.
"Advances in Genomics As Well As the More Mainstream Use of Gene Sequencing" is seen as one of major influencing trends for Orphan Diseases Market during projected period 2023-2030.

Know More About Global Orphan Diseases Market Report?

Have a Query? Click Here

Other Related Reports

Malocclusion Comprehensive Study by Type (Overcrowding, Spacing, Openbite, Overjet, Overbite, Underbite, Crossbite, Diastema, Impacted Tooth, Missing Tooth), Age Group (Children, Adults), Treatment T...
$ 3800
Membranous Nephropathy Comprehensive Study by Type (Primary Membranous Nephropathy (Idiopathic), Secondary Membranous Nephropathy), Age Group (Children, Adults), Treatment Type (Biologics, Pharmaceut...
$ 3800
Cardiovascular Application Comprehensive Study by Type (Diagnostic and Monitoring Devices, (Electrocardiogram, Holter Monitors, Event Monitors, Others), Interventional Devices, (Coronary Stents, Cath...
$ 3800
Ischemic stroke Comprehensive Study by Surgery Type (Carotid Endarterectomy, Angioplasty, Endovascular Mechanical Thrombectomy, Others), Treatment Type (Tissue Plasminogen Activator, Anticoagulant, A...
$ 3800
Depression Therapeutics- Comprehensive Study by Indication Type (Major depressive disorder (MDD), Bipolar disorder, Dysthymic disorder, Postpartum depression, Seasonal affective disorder (SAD), Preme...
$ 3800
Thyroid Disorder Therapy Comprehensive Study by Drug Type (Kinase Inhibitors, Anthracyclines, Beta-Blockers, Others), Disease Type (Hypothyroidism, Hyperthyroidism, Goiter, Hashimoto Disease, Others)...
$ 3800